Patents by Inventor Daniele Simoni

Daniele Simoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoxazole derivatives as inducers of fetal hemoglobin in erythroid precursor cells from beta-thalassemic patients
    Patent number: 11077116
    Abstract: The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in ?-thalassemia and sickle cell disease (SCD) patients.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 3, 2021
    Assignee: RARE PARTNERS SRL
    Inventors: Ilaria Lampronti, Roberto Gambari, Daniele Simoni
  • ISOXAZOLE DERIVATIVES AS INDUCERS OF FETAL HEMOGLOBIN IN ERYTHROID PRECURSOR CELLS FROM BETA-THALASSEMIC PATIENTS
    Publication number: 20200206234
    Abstract: The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in ?-thalassemia and sickle cell disease (SCD) patients.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 2, 2020
    Applicant: RARE PARTNERS SRL
    Inventors: Ilaria Lampronti, Roberto Gambari, Daniele Simoni
  • Aryl isoxazole compounds with antitumoural activities
    Patent number: 8383616
    Abstract: The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 26, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventors: Giuseppe Giannini, Walter Cabri, Daniele Simoni, Riccardo Baruchello, Claudio Pisano, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati
  • ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES
    Publication number: 20110245221
    Abstract: The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 30, 2009
    Publication date: October 6, 2011
    Applicant: SIGMA-TAU RESEARCH SWITZERLAND S.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Daniele Simoni, Riccardo Baruchello, Paolo Carminati, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati, Claudio Pisano
  • Stilbene derivatives as new cancer therapeutic agents
    Patent number: 7781580
    Abstract: Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes may also disrupt abnormal vessels in tumor to achieve vascular disrupting effect to suppress tumor growth. Water soluble pro-drug forms of stilbene derivatives are particularly useful in suppressing tumor growth in vivo.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: August 24, 2010
    Assignee: Virginia Commonwealth University
    Inventors: Ruey-min Lee, Daniele Simoni
  • STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS
    Publication number: 20080261982
    Abstract: Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes may also disrupt abnormal vessels in tumor to achieve vascular disrupting effect to suppress tumor growth. Water soluble pro-drug forms of stilbene derivatives are particularly useful in suppressing tumor growth in vivo.
    Type: Application
    Filed: April 23, 2007
    Publication date: October 23, 2008
    Inventors: Ruey-min Lee, Daniele Simoni
  • Combretastatin derivatives with cytotoxic action
    Publication number: 20060160773
    Abstract: The invention described herein relates to new combretastatin derivatives obtained by total synthesis and having the following general formula: in which the groups are as defined in the description here below. Said compounds, though chemically related to the structure of cis/trans-combretastatin, do not always bind tubulin, but nevertheless exhibit cytotoxic activity of interest in the oncological field as anticancer and/or antiangiogenic agents.
    Type: Application
    Filed: July 6, 2004
    Publication date: July 20, 2006
    Inventors: Giuseppe Giannini, Claudio Pisano, Domenico Alloatti, Romeo Romagnoli, Daniele Simoni